Ophthalmic Drugs and Devices Market—Forecast till 2030

$4,950$7,250

From 2022 to 2030, the market for ophthalmic medications and devices is anticipated to grow at a CAGR of 9.20%.

SKU: MRFR220435 Category: Tag:

Description

Ophthalmic Drugs and Devices Market—Forecast till 2030

Market Overview

From 2022 to 2030, the market for ophthalmic medications and devices is anticipated to grow at a CAGR of 9.20%. Eye diseases are treated with deep cleaning, specialist contact lenses, and other tools. The global market for ophthalmic medications and equipment is being driven by reasons like a growing older population, rising diabetes occurrences, and a growing prevalence of ocular diseases. Additionally, it is anticipated that increasing product launches and development would generate profitable growth prospects.
The first over-the-counter remedy that doctors frequently suggest is artificial tears. Eye diseases are treated with deep cleaning, specialist contact lenses, and other tools. The global market for ophthalmic medications and equipment is being driven by reasons like a growing older population, rising diabetes occurrences, and a growing prevalence of ocular diseases. Additionally, it is anticipated that increasing product launches and development would generate profitable growth prospects.

Segment Overview

Based on the product and therapy, the global market for ophthalmic medications and devices has been segmented. The market is divided into two categories based on product: pharmaceuticals and devices. Pilocarpine, Micropine, Provisc, Diuretics, Vasoconstrictors, Fluocinolone, Bimatoprost, and Others are other subcategories of the drugs category. The market is divided into the following sub-segments based on devices: Sponge Devices and Eye Cleaner, Others, Eye Massagers, Optical Dispenser, Glasses and Contact Lens, and Others. The global market for ophthalmic medications and devices has been divided into categories based on the conditions they treat, including eye infections, allergic conjunctivitis, dry eye syndrome, red eyes, inflammation, and others.

Regional Analysis

Geographically, the worldwide ophthalmic drugs and devices market, has been isolated into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is supposed to lead the worldwide market attributable to the rising predominance of eye sickness and the presence of many market players in the locale, which are driving the ophthalmic drugs and gadget market in North America. The developing geriatric populace in created nations in the district and the rising commonness of persistent eye conditions because of high pressure and undesirable ways of life bringing about diabetic retinopathy are supporting the ophthalmic drugs and devices market in Europe. The rising pace of waterfall sight misfortune issues represented a significant effect on the ophthalmic market, bringing about rising demand for ophthalmic drugs and devices in Europe.
In the Asia-Pacific district, the rising weight of ophthalmic issues and rising purchaser mindfulness are the main considerations energizing the ophthalmic drugs and devices market. Organizations are going into coordinated efforts and key drives to create and market new treatment choices for patients. The remainder of the world represented the least market share in the ophthalmic drugs and devices market. The developing headways in clinical foundation and rising health care coverage inclusion are the central point driving the development of the market in the remainder of the world.

Key Players

The prominent players in the global ophthalmic drugs and devices market are Allergan plc (Ireland), Johnson & Johnson Vision (US), Alcon (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Ocular Therapeutix, Inc. (US), Lomb Incorporated (Canada), Sight Sciences, Inc. (US), Mibo Medical Group (US), BioTissue (US), and NuSight Medical (US).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION
2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS

4.2.2 RISING GERAITRIC POPULATION

4.2.3 GROWING NUMBER OF DIABETES CASES

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS

4.3.2 SIDE EFFECTS ASSOCIATED WITH OPHTHALMIC DRUGS

4.4 OPPORTUNITIES

4.4.1 INCREASE PRODUCT DEVELOPMENT AND LAUNCHES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC DRUGS AND DEVICES MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL OPHTHALMIC DRUGS AND DEVICES MARKET, BY PRODUCT

6.1 OVERVIEW

6.2 DRUGS

6.2.1 PILOCARPINE

6.2.2 MICROPINE

6.2.3 PROVISC

6.2.4 DIURETICS

6.2.5 VASOCONSTRICTORS

6.2.6 FLUOCINOLONE

6.2.7 BIMATOPROST

6.2.8 OTHERS

6.3 DEVICES

6.3.1 GLASSES AND CONTACT LENS

6.3.2 OPTICAL DISPENSER

6.3.3 EYE MASSAGERS

6.3.4 SPONGE DEVICES AND EYE CLEANER

6.3.5 OTHERS

7 GLOBAL OPHTHALMIC DRUGS AND DEVICES MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 EYE INFECTIONS

7.3 ALLERGIC CONJUNCTIVITIS

7.4 DRY EYES SYNDROME

7.5 RED EYES

7.6 INFLAMMATION

7.7 OTHERS

8 GLOBAL OPHTHALMIC DRUGS AND DEVICES MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL OPHTHALMIC DRUGS AND DEVICES MARKET

9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC DRUGS AND DEVICES MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT APPROVAL AND PRODUCT LAUNCH

9.6.2 COLLABORATION

9.6.3 AGREEMENT

9.6.4 ACQUISITION

9.7 MAJOR PLAYERS FINANCIAL MATRIX

9.7.1 SALES (USD MILLION), 2021

9.7.2 R&D (USD MILLION), 2021

10 COMPANY PROFILES

10.1 JOHNSON AND JOHNSON VISION

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 ALLERGAN PLC

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL ANALYSIS

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 SWOT ANALYSIS

10.3.6 KEY STRATEGIES

10.4 OCULAR THERAPEUTIX, INC

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 BAUSCH & LOMB INCORPORATED

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 SWOT ANALYSIS

10.5.6 KEY STRATEGIES

10.6 SIGHT SCIENCES, INC.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL ANALYSIS

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 KEY STRATEGIES

10.7 MIBO MEDICAL GROUP

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 KEY STRATEGIES

10.8 ALCON

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS 0FFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 SWOT ANALYSIS

10.8.6 KEY STRATEGIES

10.9 BIOTISSUE

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 NUSIGHT MEDICAL

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Companies Mentioned

Allergan plc (Ireland), Johnson & Johnson Vision (US), Alcon (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Ocular Therapeutix, Inc. (US), Lomb Incorporated (Canada), Sight Sciences, Inc. (US), Mibo Medical Group (US), BioTissue (US), and NuSight Medical (US)

Reviews

There are no reviews yet.

Be the first to review “Ophthalmic Drugs and Devices Market—Forecast till 2030”